KEDRAB™: Pivotal Phase 2/3 Data presented at RITA Conference
Kedrion Biopharma and Kamada Received FDA Approval of the Product in Q3 2017
Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™
For Post-Exposure Prophylaxis Against Rabies Infection
Kedrion Biopharma volunteers at City Rescue Mission in Jacksonville, FL
US Sales & Marketing Team joined a CSR event engaging with students from CRM’s LifeBuilder program
BIVIGAM® will no longer be available for sale or distribution in 2017
Distribution agreement between Biotest and Kedrion Biopharma has been terminated
KEDPLASMA Advances Long-Range Growth Plan
KEDPLASMA acquires 2 FDA-licensed and EU-certified plasma collection centers from IMMUNOTEK
Kedrion Biopharma attends ASHP 2016 midyear clinical meeting
Kedrion Biopharma has recognized the changing role of pharmacists in the decision-making process
Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment
FDA has accepted for review a BLA for a human anti-rabies immunoglobulin (IgG) therapy
Kedrion Biopharma set for strong presence at 2016 IgNS Meeting
Kedrion Biopharma will be a bronze sponsor at the Immunoglobulin National Society (IgNS) 2016 5th National Conference
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin
Kamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDA.
Kedrion Biopharma to attend 14th International Symposium of GBS/CIPD Foundation
Kedrion Biopharma will be a Silver Sponsor at the 14th International Symposium of GBS/CIPD Foundation